SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Karuna Therapeutics, Inc. (Nasdaq – KRTX)

BALA CYNWYD – December 26, 2023 /Globe Newswire/ – Law office of Brodsky & Smith announces that it is investigating potential claims against the Board of Directors of Karuna Therapeutics, Inc. (“Karuna Therapeutics” or the “Company”) (Nasdaq – KRTX) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Bristol Myers Squibb (NYSE: BMY) in an all-cash transaction valued at approximately $14 billion. Under the terms of the agreement, Karuna Therapeutics stockholders will receive $330.00 per share in cash upon completion of the proposed transaction.

The investigation concerns whether the Karuna Therapeutics Board breached its fiduciary duties to shareholders by failing to conduct a fair process, including whether Bristol Myers Squibb is paying fair value to shareholders of the Company.

If you own shares of Karuna Therapeutics stock and wish to discuss the legal ramifications of the investigation, or have any questions, you may e-mail or call the law office of Brodsky & Smith who will, without obligation or cost to you, attempt to answer your questions. You may contact Jason L. Brodsky, Esquire, or Marc L. Ackerman by email at, or call toll free 855-576-4847.

Brodsky & Smith is a litigation law firm with extensive expertise representing shareholders throughout the nation in securities and class action lawsuits. The attorneys at Brodsky & Smith have been appointed by numerous courts throughout the country to serve as lead counsel in class actions and have successfully recovered millions of dollars for our clients and shareholders. Attorney advertising. Prior results do not guarantee a similar outcome.